Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

Coleman, R. L.

doi:10.1634/theoncologist.7-2004-46

Cited by 7 publications

(9 citation statements)

References 16 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The non-cross-resistance and different mechanisms of action between paclitaxel and topotecan provide a rationale for using topotecan alone in second-line therapy in ovarian cancer patients who have relapsed after paclitaxel first-line therapy. In addition, the results of these studies support the use of topotecan and paclitaxel in combination or sequentially in future trials for this chronic disease (see review by Coleman pp 46-55 [21]). …”

Section: Phase III Studiesmentioning

confidence: 66%

Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer

Herzog

2002

The Oncologist

View full text Add to dashboard Cite

Ovarian cancer is the fifth leading cause of cancer death in women. Most patients with ovarian cancer respond to first-line chemotherapy, but many relapse within 18 to 22 months. The development of efficacious salvage therapies that increase overall survival while maintaining quality of life is a great challenge in the treatment of this disease. Topotecan, a novel topoisomerase I inhibitor, is currently indicated for the treatment of recurrent metastatic carcinoma of the ovary. In patients with relapsed ovarian cancer, the overall response rates on treatment with topotecan range from 19%-33% in platinum-sensitive patients, 14%-18% in platinum-resistant patients, and 5%-11% in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17% in refractory and 48% in sensitive patients. In phase III studies, topotecan was shown to be equivalent in efficacy to both paclitaxel and liposomal doxorubicin as second-line therapy in patients with relapsed ovarian cancer. Further, non-cross-resistance between topotecan and paclitaxel was demonstrated in a third-line, phase III crossover study, suggesting that topotecan may be effective in the first-line setting with paclitaxel and/or platinum. Hematologic toxicities include neutropenia, thrombocytopenia, and anemia; however, these toxicities are usually short lived, noncumulative, and manageable with dose modifications, including low-dose topotecan regimens. Nonhematologic toxicities are usually mild to moderate in severity. These data support the use of topotecan for second-line therapy and suggest that topotecan may also be effective in first-line therapy. Further studies with topotecan alone and in combination with other agents are needed to fully characterize the role and sequencing of topotecan in the salvage and first-line settings. The Oncologist 2002;7(suppl 5):3-10

show abstract

Section: Phase III Studiesmentioning

confidence: 66%

Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer

Herzog

2002

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Combination chemotherapy has been most thoroughly studied. Drugs that have been studied as a third agent include etoposide (9), topotecan (10), irinotecan (11), gemcitabine (12), and anthracyclines such as doxorubicin (13).…”

Section: Introductionmentioning

confidence: 99%

Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation

Özgül¹,

Köse²,

Keskin³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

Reactions of N -isocyaniminotriphenylphosphorane with 2-oxopropyl benzoate (or 2-oxopropyl 4-bromobenzoate) in the presence of 3-phenyl-2-propynoic acid and primary amines proceeded smoothly at room temperature and in neutral conditions to afford sterically congested 1,3,4-oxadiazole derivatives in high yields. The reaction proceeded smoothly and cleanly under mild conditions and no side reactions were observed.

show abstract

“…Topotecan and irinotecan, two analogues of camptothecin, are in clinical use. In recurrent ovarian cancer, topotecan possesses antitumor activity similar to paclitaxel, with nonoverlapping side effects, and is an established treatment in second-line or salvage settings and is being investigated as a primary therapeutic alternative (1). For metastatic colorectal cancer, irinotecan was first used in salvage and evaluated in polytherapy settings (2) and is now used in first-line therapy with fluorouracil, leucovorin, and oxaliplatin (3).…”

Section: Introductionmentioning

confidence: 99%

Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin

Pond¹,

Marshall²,

Barrows³

2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The topoisomerase I (top1) -targeted camptothecin class of anticancer drugs is important in the treatment of several types of cancers. This class of drug inhibits the top1 enzyme during its catalytic DNA relaxation cycle, stabilizing the transient covalent top1-DNA complex by simultaneous noncovalent interactions with DNA and top1. We examined top1 using phage display because of the significance of this known top1-directed drug action. Several peptides that bind top1 were discovered and these were examined for top1 affinity, top1 catalytic and cleavage complex effects, and cytotoxic effects in cultured cell lines and in an in vivo tumor model. Although several peptides exhibited nanomolar and low-micromolar affinity for top1, none had cytotoxic effects when administered alone. However, in combination with 9-aminocamptothecin, one 15-mer peptide (SAYAATVRGPLSSAS) had synergistic cytotoxic effects with 9-aminocamptothecin both in the cytotoxicity assay and in nude mouse xenograft human tumor models. This report details the investigation of this peptide. [Mol Cancer Ther 2006;5(3):739 -45]

show abstract

Emerging Role of Topotecan in Front-Line Treatment of Carcinoma of the Ovary

Cited by 7 publications

References 16 publications

Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer

Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer

Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy - a retrospective evaluation

Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin

Contact Info

Product

Resources

About